跳至主要内容
临床试验/EUCTR2013-002513-35-GB
EUCTR2013-002513-35-GB进行中(未招募)1 期

A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients. - RELAX AHF_Pan E

ovartis Pharma Services AG0 个研究点目标入组 2,650 人开始时间: 2013年10月22日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
2,650

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • - Male or female = 18 years of age with body weight = 40 Kg and = 160
  • - Systolic blood pressure =125 mmHg at the beginning of the screening
  • period (after ICF signature) and at the end of the screening period (prior
  • to randomization)
  • - Admitted for AHF: Persistent dyspnea at rest or with minimal exertion,
  • Pulmonary congestion assessed through physical examination and chest
  • - Furosemide at any time between admission and the start of screening
  • - eGFR on admission: =25 and =75 mL/min/1.73 m2
  • Other protocol-defined inclusion criteria may apply.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 700
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 2483

排除标准

  • - Dyspnea (non-cardiac causes) such as acute or chronic respiratory
  • disorders or infections (i.e., severe chronic obstructive pulmonary
  • disease, bronchitis, pneumonia), or primary pulmonary hypertension
  • sufficient to cause dyspnea at rest, which may interfere with the ability
  • to interpret the primary cause of dyspnea.
  • - T >38.5°C
  • - Clinical evidence of acute coronary syndrome
  • - AHF due to arrhythmias, acute myocarditis or cardiomyopathy
  • Other protocol-defined exclusion criteria may apply.
  • Other protocol-defined exclusion criteria may apply.

研究者

相似试验